Cardiomyopathies and oxidative stress

Medical Hypotheses

Volumn 47, Issue 2, 1996, Pages 137-144

  Romero Alvira, D ^a   Roche, E ^a   Placer, L ^a  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; DAUNORUBICIN; DOXORUBICIN; SELENIUM;

ALCOHOLIC CARDIOMYOPATHY; AMYLOIDOSIS; ANTIOXIDANT ACTIVITY; CARDIOMYOPATHY; CARDIOTOXICITY; CELL DAMAGE; HUMAN; HUMAN CELL; HYPERTROPHIC CARDIOMYOPATHY; HYPOTHESIS; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW;

EID: 0029760361     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(96)90453-3     Document Type: Article

References (89)

1. Wynne J, Braunwald E. The cardiomyopathies and myocarditides. In: Wilson J D, Braunwald E, Isselbacher K J et al, eds. Principles of Internal Medicine, 12th edn. New York: McGraw-Hill, 1991: 975-981.
2. Doroshow J H, Locker G Y, Myers C E. Enzymatic defenses of the mouse heart against reactive oxygen metabolites. J Clin Invest 1980; 65: 128-135.
3. Lerner A, Wilson F M, Reyes M P. Enteroviruses and the heart (with special emphasis on the probable role of Coxsackie viruses, Group B Types 1-5). Mod Conc Cardiovasc Dis 1975; 44: 11-15.
4. Woodruff J F, Woodruff J J. Involvement of T lymphocytes in the pathogenesis of Coxsackie virus B3 heart disease. J Immunol 1974; 113: 1726-1734.
5. Reyes M P, Lerner A. Coxsackie myocarditis - with special reference to acute and chronic effects. Prog Cardiovasc Dis 1985; 27: 373-394.
6. Gear J H S, Measroch V. Coxsackie infections of the newborn. Prog Med Virol 1973; 15: 42-62.
7. Cohen I S, Anderson D W, Virmani R et al. Congestive cardiomyopathy in association with the acquired immunodeficiency syndrome. N Engl J Med 1986; 315: 628-630.
8. Perloff J K, Henze E, Schelbert H R. Alterations in regional myocardial metabolism, perfusion and wall motion in Duchenne muscular dystrophy studied by radionuclide imaging. Circulation 1984; 69: 33-42.
9. Nigro G, Comi L I, Limongelli F M et al. Prospective study of X-linked progressive muscular distrophy in Campania. Muscle Nerve 1983; 6: 253-262.
10. Frist W, Yasuda T, McDougall I R et al. Non-invasive detection of human cardiac transplant rejection with In-111 antimyosin (FAB) imaging. Circulation 1986; 74: 219.
11. Child J S, Perloff J K, Bach P M, Wolfe A D, Periman S, Kark R A. Cardiac involvement in Friedreich's ataxia. A clinical study of 75 patients. J Am Coll Cardiol 1986; 7: 1370-1378.
12. Graber H L, Unverferth D V, Baker P B, Ryan J M, Baba N, Wooley C F. Evolution of a hereditary cardiac conduction and muscle disorder: a study involving a family with six generations affected. Circulation 1986, 74: 21-35.
13. Yutani C, Imakita M, Ishibashi-Ueda H et al. Three autopsy cases of progression to left ventricular dilation in patients with hypertrophic cardiomyopathy. Am Heart J 1985; 109: 545-553.
14. Fitchett D H, Sugrue D D, McArthur C G, Oakley C M. Right ventricular dilated cardiomyopathy. Br Heart J 1984; 51: 25-29.
15. Matsumori A, Kawai C. An animal model of congestive (dilated) cardiomyopathy. Dilation and hypertrophy of the heart in the chronic stage of DBA/2 mice with myocarditis caused by encephalomyocarditis virus. Circulation 1982; 66: 355-360.
16. Woodruff J F. Viral myocarditis: a review. Am J Pathol 1980; 101: 425-484.
17. Mason J W, Billingham M E, Ricci D R. Treatment of acute inflammatory myocarditis assisted by endomyocardial biopsy. Am J Cardiol 1980; 45: 1037-1044.
18. Moriguchi J D, Stevenson L W, Kobashigawa J A et al. Decrease in 2-dimensional echocardiographic ejection fraction during transplant rejection. A study of 400 biopsies. J Am Coll Cardiol 1988; 11: 121A.
19. Haupt H M, Hutchins G M. The heart and cardiac conduction system in polymyositis - dermatomyositis, a clinicopathologic study of 16 autopsy patients. Am J Cardiol 1982; 50: 948-1006.
20. Weiss S, Stead E A Jr, Warren J Y et al. Scleroderma heart disease: with a consideration of certain other visceral manifestations of scleroderma. Arch Intern Med 1943; 71: 749-776.
21. Campbell P M, LeRoy E C. Pathogenesis of systemic sclerosis. A vascular hypothesis. Semin Arthritis Rheum 1975; 4: 351-368.
22. Clements P J, Furst D E, Cabeen W, Tashkin D, Paulus H E, Roberts N. The relationship of arrhythmias and conduction disturbances to other manifestations of cardio-pulmonary disease in progressive systemic sclerosis (PSS). Am J Med 1981; 71: 38-46.
23. Norton W L, Nardo J M. Vascular tissue in progressive systemic sclerosis (scleroderma). Ann Intern Med 1970; 73: 317-324.
24. Chrafre F M, Ross J R, Gunn E M. Eosinophilia in fatal asthma: studies of the bone marrow and myocardium. Ann Intern Med 1942; 17: 45-59.
25. Spry C J F, Davies J, Tai P C, Olsen E C J, Oakley C M, Goodwin J F. Clinical features of fifteen patients with the hypereosinophilic syndrome. Q J Med 1983; 52: 1-22.
26. Davies J, Spry C J F, Sapsford R et al. Cardiovascular features of 11 patients of eosinophilic endomyocardial disease. Q J Med 1983; 52: 23-39.
27. Herzog C A, Snover D C, Staley N A. Acute necrotizing eosinophilic myocarditis. Br Heart J 1984; 52: 343-348.
28. de Mello D E, Llams H, Jureidim S, Nouri S, Kephart G M, Gleich G J. Cardiac localization of eosinophil-granule major basic protein in acute necrotizing myocarditis. N Engl J Med 1990; 323: 1542-1545.
29. Demakis J G, Rahimtoola S H. Peripartum cardiomyopathy. Circulation 1971; 44: 964-968.
30. Homans D C. Current concepts: peripartum cardiomyopathy. N Engl J Med 1985; 312: 1432-1437.
31. Melvin K R, Richardson P J, Olsen E G J, Jackson G. Peripartum cardiomyopathy due to myocarditis. N Engl J Med 1982; 307: 731-734.
32. Midei M G, De Met S H, Feldman A M, Hutchins G M, Baughman K L. Peripartum myocarditis and cardiomyopathy. Circulation 1990; 81: 922-928.
33. Knobel B, Melamud E, Kishon Y. Peripartum cardiomyopathy. Israel J Med Sci 1984; 20: 1061.
34. Schenk E A, Cohen J. The heart in chronic alcoholism. Clinical and pathological findings. Pathol Microbiol 1970; 35: 96-104.
35. Alexander C S. Cobalt-beer cardiomyopathy. A clinical and pathologic study of twenty eight cases. Am J Med 1972; 53: 395-417.
36. Schreiber S S, Briden K, Oratz M, Rothschild M A. Ethanol, acetaldehyde and myocardial protein synthesis. J Clin Invest 1972; 51: 2820-2826.
37. +)-activated adenosine triphosphate activity of cardiac plasma membranes. Biochem Pharmacol 1975; 24: 27-32.
38. Reitz R C, Helsabeck E, Mason D P. Effects of chronic alcohol ingestion in the fatty acid composition of the heart. Lipids 1973; 8: 80-84.
39. Regan T J, Khan M I, Ettinger P O, Haider B, Lyons M M, Oldewurtel H A. Myocardial function and lipid metabolism in the chronic alcoholic animal. J Clin Invest 1974; 54: 740-752.
40. Rubin E. Alcoholic myopathy in heart and skeletal muscle. N Engl J Med 1979; 301: 28-33.
41. Puszkin S, Rubin E. Adenosine diphosphate effect on contractility of human muscle actomyosin: inhibition by ethanol and acetaldehyde. Science 1975; 188: 1319-1320.
42. Ferrans V J, Hibbs R B, Weilbaecher D C, Black W C, Walsh J J, Burch G E. Alcoholic cardiomyopathy. A histochemical study. Am Heart J 1965; 69: 748-765.
43. Alexander C S. Electron microscopic observation in alcoholic heart disease. Br Heart J 1967; 29: 200-206.
44. Tsiplenkova V G, Vikhert A M, Cherpachenko N M. Ultrastructural and histochemical observations in human and experimental alcoholic cardiomyopathy. J Am Coll Cardiol 1986; 8: 22A-32A.
45. Regan T J. Alcoholic cardiomyopathy. Prog Cardiovasc Dis 1984; 27: 141-152.
46. McDonald C D, Burch G E, Walsh J J. Alcoholic cardiomyopathy managed with prolonged bed rest. Ann Intern Med 1971; 74: 681-691.
47. Kino M. Chronic effects of ethanol under partial inhibition of catalase activity in the rat heart. Light and electron microscopic observations. J Mol Cell Cardiol 1981; 13: 5-21.
48. Pion P D, Kittleson M D, Rogers Q R, Morris J G. Myocardial failure in cats associated with low plasma taurine: a reversible cardiomyopathy. Science 1987; 237: 764-768.
49. Welty M C, Welty J D, McBroom M J. Effect of isoproterenol and taurine on heart calcium in normal and cardiomyopathic hamsters. J Mol Cell Cardiol 1982; 14: 353-357.
50. Kawai C, Matsumori A, Fujiwara H. Myocarditis and dilated cardiomyopathy. Annu Rev Med 1987; 38: 221-239.
51. Von Hoff D D, Layard M W, Basa P. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710-717.
52. Bristow M E, Minobe W A, Billingham M E et al. Anthracycline-associated cardiac and renal damage in rabbits: evidence for mediation by vasoactive substances. Lab Invest 1981; 45: 157-168.
53. Gavras H, Kremer D, Brown J J et al. Angiotensin and norepinephrine-induced myocardial lesions: experimental and clinical studies in rabbits and man. Am Heart J 1975; 89: 321-332.
54. Klugmann F B, Decorti G, Candussio L, Grill V, Mallardi F, Baldini L. Inhibitors of adriamycin-induced histamine release in vitro limit adriamycin cardiotoxicity in vivo. Br J Cancer 1986; 54: 743-748.
55. Fujita K, Shinpo K, Yamada K et al. Reduction of adriamycin toxicity by ascorbate in mice and guinea pigs. Cancer Res 1982; 42: 309-316.
56. Kien C L, Ganther H E. Manifestation of chronic selenium deficiency in a child receiving total parenteral nutrition. Am J Clin Nutr 1983; 37: 319-328.
57. Olson R D, Boerth R C, Gerber J G, Nies A S. Mechanism of adriamycin cardiotoxicity evidence for oxidative stress. Life Sci 1981; 29: 1393-1401.
58. Thayer W S. Decreased cardiac lipoprotein lipase activity in rats treated chronically with adriamycin. Life Sci 1985; 36: 635-641.
59. Muindi J, Sinha B K, Giani L, Myers C. Thiol-dependent DNA damage produced by anthracycline-iron complexes. The structure-activity relationship and molecular mechanics. Mol Pharmacol 1985; 27: 356-365.
60. McFalls E O, Paulson D J, Gilbert E F, Shug A L. Carnitine protection against adriamycin-induced cardiomyopathy in rats. Life Sci 1986; 38: 497-505.
61. York C M, Cantrell C R, Borum P R. Cardiac carnitine deficiency and altered transport in cardiomyopathic hamsters. Arch Biochem Biophys 1983; 221: 526-533.
62. Whitmer J T. Energy metabolism and mechanical function in perfused hearts of Syrian hamsters with dilated or hypertrophic cardiomyopathy. J Mol Cell Cardiol 1986; 18: 307-317.
63. Whitner J T. L-carnitine treatment improves cardiac performance and restores high-energy phosphate pools in cardiomyopathic Syrian hamster. Circ Res 1987; 61: 396-408.
64. Herman E F, Ferrans V J. Pretreatment with ICRF-187 provides long-lasting protection against chronic daunorubicin cardiotoxicity in rabbits. Cancer Chemother Pharmacol 1986; 16: 102-106.
65. Ge K, Xue A, Bai J, Wang S. Keshan disease - an endemic cardiomyopathy in China. Virchows Arch Pathol Anat 1983; 401: 1-15.
66. Keshan Disease Research Group of the Chinese Academy of Medical Science. Epidemiologic studies on the etiologic relationship of selenium and Keshan disease. Chin Med J Engl 1979; 92: 477-482.
67. Guanqing H. On the etiology of Keshan disease: two hypotheses. Chin Med J Engl 1979; 92: 416-422.
68. Keshan Disease Research Group of the Chinese Academy of Medical Science. Observations on effect of sodium selenite in the prevention of Keshan disease. Chin Med J Engl 1979; 92: 471-476.
69. Sizer F, Whitney E. Nutrition, concepts and controversies, 6th edn. Minneapolis, MN: West Publishing Company, 1994.
70. Johnson R A, Baker S S, Fallon J T et al. An occidental case of cardiomyopathy and selenium deficiency. N Engl J Med 1981; 304: 1210-1212.
71. Collip P J, Chen S Y. Cardiomyopathy and selenium deficiency in a two year old girl. N Engl J Med 1981; 304: 1304-1305.
72. Kawai C, Wakabayashi A, Matsumura T, Yui Y. Reappearance of beri-beri heart disease in Japan. Am J Med 1980; 69: 383-386.
73. Forfar J C, Muir A L, Sawers S A, Toft A D. Abnormal left ventricular function in hyperthyroidism. N Engl J Med 1982; 307: 1165-1170.
74. Colucci W S, Braunwald E. Cardiac tumors, cardiac manifestations of systemic diseases, and traumatic cardiac injury. In: Wilson J D, Braunwald E, Isselbacher K J et al. Principles of Internal Medicine, 12th edn. New York: McGraw-Hill, 1991: 988-991.
75. Olson L J, Edwards W D, McCall J T, Ilstrup D M, Gersh B J. Cardiac iron deposition in idiopathic hemochromatosis: histologic and analytic assessment of 14 hearts from autopsy. J Am Coll Cardiol 1987; 10: 1239-1243.
76. Batist G, Mersereau W, Malashenko B A, Chiu R C. Response to ischemia-reperfusion injury in hypertrophic heart. Role of free-radical metabolic pathways. Circulation 1989; 80: 11110-11113.
77. Singal P K, Kirshembaum L A. A relative deficit in antioxidant reserve may contribute in cardiac failure. Can J Cardiol 1990; 6: 47-49.
78. Teare R D. Asymmetrical hypertrophy of heart in young adults. Br Heart J 1958; 20: 1-8.
79. Maron J B, Epstein S E, Roberts W C. Hypertrophic cardiomyopathy and transmural myocardial infarction without significant atherosclerosis of the extramural coronary arteries. Am J Cardiol 1979; 43: 1086-1102.
80. St John Sutton M G, Lie J T, Anderson K R, O'Brien P C, Frye R L. Histopathological specificity of hypertrophic obstructive cardiomyopathy. Myocardial fibre disarray and myocardial fibrosis. Br Heart J 1980; 44: 433-443.
81. Tanaka M, Fujiwara H, Onodera T, Wu D-J, Hamashima Y, Kawai C. Quantitative analysis of myocardial fibrosis in normal, hyprtensive hearts, and hypertrophic cardiomyopathy. Br Heart J 1986; 55: 575-581.
82. Goodwin J F. Prospects and predictions for the cardiomyopathies. Circulation 1974; 50: 210-219.
83. Maron B J, Bonow R O, Cannon R O, Leon M B, Epstein S E. Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology and therapy. Part 1. N Engl J Med 1987; 316: 780-789.
84. Wigle E D, Sasson Z, Henderson M A et al. Hypertrophic cardiomyopathy. The importance of the site and extent of hypertrophy: a review. Prog Cardiovasc Dis 1985; 28: 1-83.
85. Gaasch W H, Levine H J, Quinones M A, Alexander J K. Left ventricular compliance: mechanisms and clinical implications. Am J Cardiol 1976; 38: 645-653.
86. Floge J, Granolleras C, Shaldon S, Koch K M. Dialysis associated amyloidosis and B 2 M. Contr Nephrol 1988; 61: 27-38.
87. Deschamps-Latscha B. Phagocyte oxidative metabolism in hemodialysis. Contr Nephrol 1988; 62: 132-139.
88. Tetta C, Segoloni G, Camussi G, Piva S, Vercellone A. Biocompatibility of hemodialysis (HD) membranes. The role of endocellular mediator in HD associated neutropenia. Nefrologia 1987; 7: 30-34.
89. Horl W H. Activation of granulocytes during hemodialysis: effects of different dialyser membranes. Nefrologia 1987; 7: 65-71.